Company profile
Monopar Therapeutics
NASDAQ:MNPRBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05043649 | phase1 | terminated | 2021-09-22 | 2023-10-31 | Monopar Therapeutics | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS |
| NCT04648020 | phase2_3 | terminated | 2021-02-11 | 2023-05-14 | Monopar Therapeutics | Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. |
| NCT06337084 | phase1 | active_not_recruiting | 2024-05-30 | 2026-12-01 | Monopar Therapeutics | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors |
| NCT06617169 | phase1 | active_not_recruiting | 2024-10-08 | 2027-01-01 | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors |
FDA applications (0)
No records yet.